Faithful modeling of terminal CD8+T cell dysfunction and epigenetic stabilization in vitro.

IF 6.1 1区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
Amir Yousif, Abbey A Saadey, Ava Lowin, Asmaa M Yousif, Ankita Saini, Madeline R Allison, Kelley Ptak, Eugene M Oltz, Hazem E Ghoneim
{"title":"Faithful modeling of terminal CD8+T cell dysfunction and epigenetic stabilization in vitro.","authors":"Amir Yousif, Abbey A Saadey, Ava Lowin, Asmaa M Yousif, Ankita Saini, Madeline R Allison, Kelley Ptak, Eugene M Oltz, Hazem E Ghoneim","doi":"10.1172/jci.insight.191220","DOIUrl":null,"url":null,"abstract":"<p><p>Epigenetic scarring of terminally dysfunctional (TDysf) CD8+ T cells hinders long-term protection and response to immune checkpoint blockade during chronic infections and cancer. We developed a faithful in vitro model for CD8+ T cell terminal dysfunction as a platform to advance T cell immunotherapy. Using TCR-transgenic CD8+ T cells, we found that 1-week peptide stimulation, mimicking conditions in previous models, failed to induce a stable exhaustion program. In contrast, prolonged stimulation for 2-3 weeks induced T cell dysfunction but triggered activation-induced cell death, precluding long-term investigation of exhaustion programs. To better mimic in vivo exhaustion, we provided post-effector, chronic TGF-β1 signals, enabling survival of chronically stimulated CD8+ T cells for over 3 weeks. These conditions induced a state of terminal dysfunction, marked by a stable loss of effector, cytotoxicity, and memory programs, along with mitochondrial stress and impaired protein translation. Importantly, transcriptomic and epigenetic analyses verified the development of terminal exhaustion-specific signatures in TDysf cells. Adoptive transfer of TDysf cells revealed their inability to recall effector functions or proliferate after acute lymphocytic choriomeningitis virus rechallenge. This tractable model system enables investigation of molecular pathways driving T cell terminal dysfunction and discovery of therapeutic targets for cancer or chronic infections.</p>","PeriodicalId":14722,"journal":{"name":"JCI insight","volume":"10 19","pages":""},"PeriodicalIF":6.1000,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12513483/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCI insight","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1172/jci.insight.191220","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Epigenetic scarring of terminally dysfunctional (TDysf) CD8+ T cells hinders long-term protection and response to immune checkpoint blockade during chronic infections and cancer. We developed a faithful in vitro model for CD8+ T cell terminal dysfunction as a platform to advance T cell immunotherapy. Using TCR-transgenic CD8+ T cells, we found that 1-week peptide stimulation, mimicking conditions in previous models, failed to induce a stable exhaustion program. In contrast, prolonged stimulation for 2-3 weeks induced T cell dysfunction but triggered activation-induced cell death, precluding long-term investigation of exhaustion programs. To better mimic in vivo exhaustion, we provided post-effector, chronic TGF-β1 signals, enabling survival of chronically stimulated CD8+ T cells for over 3 weeks. These conditions induced a state of terminal dysfunction, marked by a stable loss of effector, cytotoxicity, and memory programs, along with mitochondrial stress and impaired protein translation. Importantly, transcriptomic and epigenetic analyses verified the development of terminal exhaustion-specific signatures in TDysf cells. Adoptive transfer of TDysf cells revealed their inability to recall effector functions or proliferate after acute lymphocytic choriomeningitis virus rechallenge. This tractable model system enables investigation of molecular pathways driving T cell terminal dysfunction and discovery of therapeutic targets for cancer or chronic infections.

终末CD8+T细胞功能障碍和体外表观遗传稳定的忠实建模。
在慢性感染和癌症期间,终末功能失调(TDysf) CD8+ T细胞的表观遗传瘢痕阻碍了对免疫检查点封锁的长期保护和反应。我们开发了一个可靠的CD8+ T细胞终末功能障碍的体外模型,作为推进T细胞免疫治疗的平台。使用tcr转基因CD8+ T细胞,我们发现1周的肽刺激,模仿先前模型的条件,未能诱导稳定的衰竭程序。相比之下,2-3周的长时间刺激诱导T细胞功能障碍,但引发激活诱导的细胞死亡,排除了对衰竭程序的长期研究。为了更好地模拟体内衰竭,我们提供了后效的慢性TGF-β1信号,使慢性刺激的CD8+ T细胞存活超过3周。这些条件诱导了一种终末功能障碍状态,其特征是效应、细胞毒性和记忆程序的稳定丧失,以及线粒体应激和蛋白质翻译受损。重要的是,转录组学和表观遗传学分析证实了TDysf细胞中终端衰竭特异性特征的发展。TDysf细胞的过继转移表明,在急性淋巴细胞性脉络丛脑膜炎病毒再攻击后,它们无法回忆起效应功能或增殖。这个易于处理的模型系统可以研究驱动T细胞终端功能障碍的分子途径,并发现癌症或慢性感染的治疗靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
JCI insight
JCI insight Medicine-General Medicine
CiteScore
13.70
自引率
1.20%
发文量
543
审稿时长
6 weeks
期刊介绍: JCI Insight is a Gold Open Access journal with a 2022 Impact Factor of 8.0. It publishes high-quality studies in various biomedical specialties, such as autoimmunity, gastroenterology, immunology, metabolism, nephrology, neuroscience, oncology, pulmonology, and vascular biology. The journal focuses on clinically relevant basic and translational research that contributes to the understanding of disease biology and treatment. JCI Insight is self-published by the American Society for Clinical Investigation (ASCI), a nonprofit honor organization of physician-scientists founded in 1908, and it helps fulfill the ASCI's mission to advance medical science through the publication of clinically relevant research reports.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信